AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2 Study for Psoriatic Arthritis

 AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2 Study for Psoriatic Arthritis

AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2 Study for Psoriatic Arthritis

Shots:

  • The P-III SELECT-PsA 2 study involves assessing of Rinvoq (15/30mg) vs PBO in adult patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease-modifying anti-rheumatic drugs (bDMARDs)
  • The P-III SELECT-PsA 2 study results: @12wks. patients achieved ACR20 (57%/64% vs 24%), ACR 50(32%/38% vs 5%), ACR 70 (9%/17% vs 0.5%); @16wks. patients achieved PASI 75 (52%/57% vs 16%); @24wks. patients achieved minimal disease activity (25%/29% vs 3%); safety profile was consistent with the previous studies with no new safety risks detected
  • RINVOQ is a selective and reversible JAK inhibitor, developed by Amgen, currently being studied for once-daily therapy in psoriatic arthritis and multiple immune-mediated diseases

Click here to­ read full press release/ article | Ref: AbbVie | Image:  Science

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post